Clinical Trial Update: Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase IIb study of AST-3424 in AKR1C3-high expressing advanced hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AST-3424 (AST-3424)

Snippet

Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. | Conditions: HCC - Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING